Oral Insulin
Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus

Type of Study:
Adults 18 years and older with 2 Diabetes needing insulin

Study Length:
Up to 52 weeks

Target Age/Sex:
18 years – 75 years, Male and Female, with a diagnosis of Type 2 Diabetes

Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Enrolling


In this randomized, double-blind, double-dummy, placebo-controlled study, approximately 675 eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3 oral glucose-lowering agents will undergo an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period and a 26-week Double-Blind Treatment Extension Period.

Enroll Now

Enroll Now

If you don't have a primary care physician, just type "Do not have a primary care physician"